They were 18.7% in sporadic CRC and 16.4% in LS CRC, respectively; significant associations were observed between MLH1 promoter methylation and gender, tumor location, tumor differentiation, MSI, MLH1 protein expression, and BRAF mutation. This evidence concerns the gene BRAF and Leigh syndrome.